June 29, 2026

FDA 503B GLP-1 Exclusion Comment Deadline Closes Today, Medicare GLP-1 Bridge Mainstream-Media Coverage Wave, PCAC Oral Testimony Closes Tuesday, Zymeworks-Theravance $929M Acquisition, Pharmacy Times Lambert Pharmacist Guidance, Leerink Cherny Calls PCAC 'Modest Binary Event' for HIMS

FDA 503B GLP-1 comments close today; Medicare Bridge media wave; PCAC testimony Tuesday; Zymeworks-Theravance $929M; pharmacist guidance; HIMS analyst notes.

6 stories · Covering regulatory, industry

Editor's Note

Monday opens the federal regulatory week that closes the door on bulk GLP-1 compounding by 503B outsourcing facilities and opens it for the Medicare GLP-1 Bridge demonstration. The 503B comment window on the FDA's proposed permanent exclusion of semaglutide, tirzepatide, and liraglutide from the bulks list closes at 11:59 PM ET tonight (docket 2026-08552, Federal Register May 1). National Community Pharmacists Association and Alliance for Pharmacy Compounding are filing position papers arguing for retention of bulk-compounding pathways during continuing patient-access gaps; Partnership for Safe Medicines and the FDA's CDER drug safety arm support the exclusion. Wolters Kluwer's Annie Lambert published guidance in Pharmacy Times advising pharmacists to demonstrate fluency in the new regulatory rules and to help patients weigh manufacturer-assistance programs and direct-to-consumer access channels. The mainstream-media explainer wave for Wednesday's Medicare GLP-1 Bridge launch hit the Washington Post, CBS News, and CNBC across the weekend, with each outlet emphasizing that this is the first time Medicare will help pay for obesity-only-indication GLP-1 prescriptions. On the non-GLP-1 track, PCAC oral testimony registration closes tomorrow Tuesday June 30 for the July 23-24 hearing that will vote 503A bulks list eligibility for BPC-157, KPV, TB-500, MOTS-c, Emideltide/DSIP, Semax, and Epitalon. Industry consolidation continued with Zymeworks announcing a $929 million cash acquisition of Theravance Biopharma at $17.00 per share plus a CVR on ampreloxetine, gaining access to the FDA-approved nebulized COPD drug Yupelri. Analyst notes ahead of PCAC included Leerink's Michael Cherny calling the July 23-24 meeting a 'modest binary event' for Hims & Hers and Canaccord Genuity reiterating a Buy rating with a $32 price target, framing peptides as a long-term wellness-and-longevity growth driver.

Regulatory

FDA 503B GLP-1 Exclusion Public Comment Window Closes 11:59 PM ET Today Monday June 29 (Docket 2026-08552): National Community Pharmacists Association, Alliance for Pharmacy Compounding, Partnership for Safe Medicines Among Stakeholders Filing Final Comments on Proposed Permanent Exclusion of Semaglutide, Tirzepatide, and Liraglutide from 503B Bulks List

The FDA's public comment window on the proposed permanent exclusion of semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and liraglutide (Victoza, Saxenda) from the 503B bulks list closes Monday June 29, 2026 at 11:59 PM ET. The proposal (Federal Register notice May 1, docket 2026-08552) cited 'no clinical need' for outsourcing facilities to compound these drugs from bulk substances given commercial availability of the branded products. The final-comment filers split along expected lines. National Community Pharmacists Association (NCPA) and Alliance for Pharmacy Compounding (APC) argue for retention given continuing patient-access gaps for high-cost branded supply, particularly in rural and underserved markets where Hims & Hers and LifeMD telehealth penetration is lower. Partnership for Safe Medicines and the FDA's CDER drug safety arm support the exclusion, citing more than 455 adverse event reports linked to compounded semaglutide and 320+ reports tied to compounded tirzepatide as of early 2025, with a large fraction involving patient self-dosing errors from multidose vials. The FDA will publish its final determination in the Federal Register within several months of comment closure. Once finalized, large-scale compounded GLP-1 distribution through 503B outsourcing facilities ends; patient-specific 503A compounding may continue under narrow circumstances.

#fda #503b #bulks-list #semaglutide #tirzepatide #liraglutide #ncpa #alliance-for-pharmacy-compounding #partnership-for-safe-medicines #glp-1-compounding

Industry

Mainstream-Media Explainer Wave for Medicare GLP-1 Bridge Demonstration (Launches Wednesday July 1, 2 Days Out): Washington Post, CBS News, and CNBC Publish Consumer-Facing Guides on the First Medicare Coverage of Obesity-Only GLP-1 Prescriptions at $50/Month Copay Through Humana Central Processing for Foundayo, Wegovy, and Zepbound KwikPen

Mainstream-media coverage of the Medicare GLP-1 Bridge demonstration intensified through the weekend ahead of Wednesday's July 1 launch. The Washington Post published 'Medicare is about to cover GLP-1 drugs for weight loss. Here's what to know' on June 29; CBS News ran a parallel explainer the same day; CNBC's June 28 piece flagged that a large share of eligible seniors may not yet know about the coverage expansion. The shared message across the three outlets: the program is the first time Medicare will help pay for drugs prescribed solely for obesity (rather than for diabetes, cardiovascular risk, or another approved indication), the $50/month copay applies to Foundayo (orforglipron tablets), Wegovy (injection and 1.5/4/9/25 mg tablets), and Zepbound KwikPen, the demonstration runs through December 31, 2027, and Humana acts as the single central processor for prior authorization and claims adjudication. CMS estimates several hundred thousand Medicare Part D beneficiaries will qualify under the three-tier BMI eligibility framework (BMI ≥35; BMI ≥30 with comorbid heart failure, uncontrolled hypertension, or chronic kidney disease; BMI ≥27 with prediabetes, prior MI, prior stroke, or peripheral artery disease). The Bridge transitions to the broader BALANCE Model launching January 2027 in Medicare Part D.

#medicare-glp-1-bridge #cms #humana #washington-post #cbs-news #cnbc #mainstream-media #july-1-launch #obesity-coverage #consumer-education

Regulatory

PCAC Oral Testimony Registration Window Closes Tuesday June 30 (1 Day Out) for July 23-24 Pharmacy Compounding Advisory Committee Meeting on 503A Bulks List Eligibility for BPC-157, KPV, TB-500, MOTS-c, Emideltide/DSIP, Semax, and Epitalon

Registration for oral testimony at the FDA Pharmacy Compounding Advisory Committee (PCAC) meeting on July 23-24, 2026 closes Tuesday June 30, 2026 — one day from this Monday digest. The two-day meeting at the FDA White Oak campus in Silver Spring, Maryland (with virtual attendance option) will vote on 503A bulks list eligibility for seven peptides: BPC-157, KPV, TB-500, and MOTS-c on Day 1 (July 23); Emideltide (delta sleep-inducing peptide / DSIP), Semax, and Epitalon on Day 2 (July 24). Pharmacist-facing guidance in Pharmacy Times (Annie Lambert, PharmD, BCSCP, Wolters Kluwer clinical program manager for compliance solutions, published two days ago) advised compounding pharmacies to prepare for the post-PCAC market regardless of which specific peptides receive affirmative votes. Written comments to docket FDA-2025-N-6895 remain open through July 22 at 11:59 PM ET. The seven peptides came off the FDA's Category 2 'do not compound' list effective April 23, 2026; PCAC affirmative votes plus FDA acceptance are needed for formal 503A bulks list addition. Hims & Hers (HIMS), LifeMD, Henry Meds, and the broader telehealth-peptide platform space have priced in some affirmative outcomes (Barclays $39 HIMS PT, June 17; Leerink Market Perform reiteration this past week).

#pcac #fda #503a #bulks-list #bpc-157 #kpv #tb-500 #mots-c #emideltide #semax #epitalon #oral-testimony #peptide-compounding

Industry

Zymeworks Announces $929 Million Cash Acquisition of Theravance Biopharma at $17.00 Per Share Plus CVR on Ampreloxetine Future Monetization, Gaining the FDA-Approved Nebulized COPD Drug Yupelri to Anchor a Respiratory Franchise Against GSK, AstraZeneca, and Boehringer Ingelheim

Zymeworks (NASDAQ: ZYME) announced Monday June 29, 2026 a definitive agreement to acquire Theravance Biopharma (NASDAQ: TBPH) for $17.00 per share in cash, an equity value of approximately $929 million plus a contingent value right (CVR) entitling Theravance shareholders to 80% of net proceeds from any future license, divestiture, or monetization of ampreloxetine (the late-stage program that posted topline results from the Phase 3 CYPRESS study on March 3, 2026, prompting the buyout window). The $17.00 price represents a 22% premium to Theravance's March 3 closing price and a 10% premium to the volume-weighted average price since that date. Financing comes from a $350 million non-recourse note secured by the US YUPELRI profit share from OMERS Life Sciences, plus Theravance's expected $360 million net cash balance at closing. The strategic anchor is YUPELRI (revefenacin), a once-daily nebulized long-acting muscarinic antagonist for COPD that competes against GSK's Trelegy, AstraZeneca's Bevespi, and Boehringer Ingelheim's Spiriva Respimat. The transaction is expected to close in H2 2026 subject to Theravance shareholder approval and regulatory clearances. Industry context: the deal sits inside a late-June biotech consolidation wave that also produced AbbVie's $10.9B Apogee Therapeutics acquisition (June 22, anti-IL-13 zumilokibart) and Sangamo's Chapter 11 with Lilly's $50M stalking-horse bid on capsid, zinc finger, MINT, and ST-506 prion-disease assets (June 23).

#zymeworks #theravance-biopharma #acquisition #yupelri #ampreloxetine #copd #biotech-consolidation #industry-deals

Regulatory

Pharmacy Times (June 27): Wolters Kluwer's Annie Lambert PharmD on How Pharmacists Should Respond to FDA's GLP-1 Compounding Narrowing — 503A Compounding Continues Under Increased Scrutiny, Patients Should Verify Pharmacy Licensure and Compounded vs FDA-Approved Distinction

Pharmacy Times published an interview with Annie Lambert, PharmD, BCSCP, Wolters Kluwer's clinical program manager for compliance solutions, on Friday June 27, 2026, walking pharmacists through the operational response to the FDA's proposed exclusion of semaglutide, tirzepatide, and liraglutide from the 503B bulks list. Three working points framed the guidance: the FDA's move signals a narrowing of large-scale compounding rather than an outright ban (503A pharmacies can still compound these agents under increased scrutiny); pharmacists should demonstrate fluency in the new regulatory rules and help patients weigh manufacturer-assistance programs (NovoCare $149-499/month, LillyDirect $299-449/month self-pay), direct-to-consumer channels, and the Medicare GLP-1 Bridge launching Wednesday July 1; patients should verify pharmacy licensure, question medication sourcing, and understand the distinction between FDA-approved branded products and compounded preparations. The guidance is the highest-profile professional-practice resource published in the comment-deadline week and is likely to circulate widely among the National Community Pharmacists Association and Alliance for Pharmacy Compounding memberships.

#pharmacy-times #annie-lambert #wolters-kluwer #pharmacist-guidance #glp-1-compounding #503a #503b #patient-education

Industry

Leerink's Michael Cherny Calls July 23-24 PCAC Meeting a 'Modest Binary Event' for Hims & Hers (HIMS) with Real Upside Beginning FY27+ if Affirmative Vote Lands, Canaccord Genuity Reiterates Buy at $32 Price Target on Long-Term Peptide-Wellness-Longevity Thesis

Analyst coverage of Hims & Hers (NYSE: HIMS) ahead of the July 23-24 PCAC meeting consolidated through the weekend with two distinct framings. Leerink Partners' Michael Cherny called the PCAC vote a 'modest binary event,' acknowledging that an affirmative outcome on BPC-157, KPV, TB-500, MOTS-c, Emideltide/DSIP, Semax, or Epitalon would open real upside starting FY2027 and beyond (peptides as a large new product category for the company's owned California compounding facility), while flagging the procedural caveat that PCAC votes have a mixed record and the FDA does not always follow committee recommendations. Canaccord Genuity reiterated a 'Buy' rating on HIMS with a $32 price target framing peptides as part of the company's long-term preventive-health, longevity, and wellness portfolio expansion. The two analyst views sit alongside Barclays' June 17 PT raise to $39 (Overweight, weight-loss-momentum thesis). HIMS stock entered Monday June 29 up roughly 29.79% in June despite a 1.62% intraday decline, with the convergence of analyst price targets and the binary July 23-24 PCAC catalyst positioning the company as one of the most-watched names in the obesity-and-longevity telehealth space heading into Q3 2026.

#hims-hers #leerink #michael-cherny #canaccord-genuity #pcac #analyst-rating #peptide-catalyst #wellness-longevity